Z-338. Zeria/Yamanouchi.
Zeria and Yamanouchi are co-developing Z-338, a thiazole-4-carboxamide derivative with prokinetic activities, as a potential treatment for dyspepsia and gastric motility disorders. This compound is currently in phase II clinical trials.
Lehmann
Anders
A
Integrative Pharmacology, Gastrointestinal Biology, AstraZeneca R&D Mölndal, Sweden. anders.lehmann@astrazeneca.com
D000818:Animals; D001549:Benzamides / Q000138:chemical synthesis / Q000378:metabolism / Q000494:pharmacology*; D001682:Biological Availability; D002800:Cholinesterase Inhibitors / Q000008:administration & dosage / Q000378:metabolism / Q000493:pharmacokinetics; D017322:Clinical Trials, Phase II as Topic; D004285:Dogs; D004333:Drug Administration Routes; D004353:Drug Evaluation, Preclinical / Q000379:methods; D004345:Drug Industry; D015507:Drugs, Investigational; D004415:Dyspepsia / Q000188:drug therapy; D005765:Gastrointestinal Agents / Q000138:chemical synthesis / Q000378:metabolism / Q000494:pharmacology; D005767:Gastrointestinal Diseases / Q000188:drug therapy; D005769:Gastrointestinal Motility / Q000187:drug effects; D006168:Guinea Pigs; D006801:Humans; D006993:Hypnotics and Sedatives / Q000008:administration & dosage / Q000378:metabolism / Q000493:pharmacokinetics; D015394:Molecular Structure; D015337:Multicenter Studies as Topic; D051381:Rats; D043643:Receptor, Muscarinic M1 / Q000187:drug effects / Q000502:physiology / Q000627:therapeutic use; D043585:Receptor, Muscarinic M2 / Q000187:drug effects / Q000502:physiology / Q000627:therapeutic use; D013548:Sweden; D013844:Thiazoles / Q000138:chemical synthesis / Q000378:metabolism / Q000494:pharmacology*; D014981:Xenopus
D001549:Benzamides; D002800:Cholinesterase Inhibitors; D015507:Drugs, Investigational; D005765:Gastrointestinal Agents; D006993:Hypnotics and Sedatives; D043643:Receptor, Muscarinic M1; D043585:Receptor, Muscarinic M2; D013844:Thiazoles; C410959:Z 338